2014 2013 2012 2011 2010 Archives

  • March 21, 2014

    Marit Aure Places 2nd in the AADR/Johnson & Johnson Hatton Awards Competition.

    Marit Aure, a Postdoctoral Associate from Catherine Ovitt's lab, has earned 2nd place in the AADR/Johnson & Johnson Hatton Awards Competition. She will now compete in the IADR Unilever Hatton Competition and Awards at the 92nd General Session & Exhibition of the IADR in Cape Town, South Africa, June 25-28, 2014.

    Congratulations Marit!

  • March 13, 2014

    Researchers Awarded $3.5 Million in NYS Stem Cell Grants

    Six scientists from the University of Rochester School of Medicine and Dentistry have been recommended awards of more than $3.5 million by NYSTEM. The grants are for a wide range of research programs in the fields of neurological disorders, bone growth and repair, and cancer.

    The diversity of these awards demonstrates that stem cell biology has become an essential research tool in a wide range of diseases, said Mark Taubman, M.D., dean of the School of Medicine and Dentistry. State investments in stem cell research – both for individual research programs and to create resources such as the Upstate Stem Cell cGMP Facility – has enabled many promising discoveries in this field to continue to move forward. In many instances, this research may have otherwise stalled for lack of funding support from other sources.

    Among the 6 researchers are Biomedical Genetics' own Wei Hsu, Mark Noble, Margot Mayer-Pröschel and Jianwen Que.

  • February 10, 2014

    Local Researchers Develop Possible Treatment for Parkinson's

    Researchers in Rochester have developed a new cell therapy that could treat Parkinson’s disease, a neurological disorder which affects motor function. The study from the University of Rochester Medical Center suggests this new approach could not only halt progression of the disease, but also reverse its impact on the brain.

    Now, researchers have found a way to use supporter cells known as astrocytes to spur wider recovery throughout the brain. So we can think of them as a work crew that delivers multiple tools at the same time, each of which can target a different cell population, says lead author Chris Proschel.

    Proschel says they were careful to begin their treatment only after their lab mice had developed signs of Parkinson’s disease. He says this delay is important because it mimics the way therapies are actually used in humans, where damage has occurred and symptoms have presented before any treatment is carried out.

  • January 28, 2014

    Finding Points to Possible New Parkinson’s Therapy

    A new study shows that, when properly manipulated, a population of support cells found in the brain called astrocytes could provide a new and promising approach to treat Parkinson’s disease. These findings, which were made using an animal model of the disease, demonstrate that a single therapy could simultaneously repair the multiple types of neurological damage caused by Parkinson’s, providing an overall benefit that has not been achieved in other approaches.

    One of the central challenges in Parkinson’s disease is that many different cell types are damaged, each of which is of potential importance, said Chris Proschel, Ph.D., an assistant professor of Biomedical Genetics at the University of Rochester Medical Center (URMC) and lead author of the study which appears today in the European journal EMBO Molecular Medicine. However, while we know that the collective loss of these cells contributes to the symptoms of the disease, much of the current research is focused on the recovery of only one cell type.


Photo of Dirk Bohmann
Dirk Bohmann, Ph.D. Program Director

Apply Now!

For more information and details on how to apply please visit the Office for Graduate Education and Postdoctoral Affairs.